Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation‐predominant irritable bowel syndrome

@article{Tack2006PilotSO,
  title={Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation‐predominant irritable bowel syndrome},
  author={Jan Tack and Stephen J. Middleton and Margaret Horne and Hubert Piessevaux and Jonathon Bloor and Nicholas L Meyers and R M Palmer},
  journal={Alimentary Pharmacology \& Therapeutics},
  year={2006},
  volume={23}
}
To investigate the efficacy and safety of renzapride, a potent 5‐hydroxytryptamine type‐4 receptor full agonist and 5‐hydroxytryptamine type‐3 receptor antagonist in patients with constipation‐predominant irritable bowel syndrome. 
Clinical trial: renzapride therapy for constipation‐predominant irritable bowel syndrome – multicentre, randomized, placebo‐controlled, double‐blind study in primary healthcare setting
TLDR
This study highlights the need for new and effective medicines to be urgently required for treating patients with irritable bowel syndrome.
Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome
TLDR
Renzapride is a mixed 5-hydroxytryptamine type 4 (5-HT4) agonist and 5-HT3 receptor antagonist that has a stimulatory effect on gastrointestinal motility and transit, as established by in vivo and in vitro studies.
Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients
TLDR
Renzapride is not superior to placebo in relieving IBS symptoms and causes significant incidences of diarrhea and drop-outs due to adverse effects in treated patients vs. placebo, suggesting this medicine might be a cost burden to patients without providing good effectiveness.
Mechanisms of serotonergic agents for treatment of gastrointestinal motility and functional bowel disorders
  • S. Kindt, J. Tack
  • Medicine
    Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2007
TLDR
This review focuses on the known effects of selective serotonin reuptake inhibitor and serotonin receptor agonists and antagonists on the sensorimotor function of the GI tract and describes the therapeutic potential of these actions for GI motility and functional bowel disorders.
Prucalopride for constipation
TLDR
Prucalopride is an efficacious and generally safe, new therapeutic option in the management of chronic constipation, and this review concluded that this drug should be considered as a first-line treatment for constipation in elderly patients.
Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders
TLDR
The nonselective 5‐HT4 receptor agonists, cisapride and tegaserod have been associated with cardiovascular adverse events (AEs) and the use of these drugs in clinical practice is still under investigation.
[Novel therapeutic approaches in the treatment of irritable bowel syndrome].
TLDR
Albeit nowadays several drugs (alosetron, tegaserod) have been registered in a few countries for the treatment of irritable bowel syndrome, further large clinical trials are required related to the new chemical entities.
Update on constipation: one treatment does not fit all.
TLDR
Sometimes the key to improvement and patient satisfaction is to understand the mechanism and the patient, as well as the patient and the mechanism.
Prucalopride: a new drug for the treatment of chronic constipation
  • J. Tack
  • Medicine
    Expert review of gastroenterology & hepatology
  • 2009
TLDR
Prucalopride belongs to a novel class of 5-hydroxytryptamine-4 receptor agonists, and has been evaluated extensively for the treatment of chronic constipation, and shows consistent efficacy and excellent tolerability.
Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation
TLDR
Prucalopride is a well tolerated and efficacious prokinetic medication that should enhance the treatment of chronic constipation unresponsive to first-line treatments.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 56 REFERENCES
Tegaserod, a 5‐HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation
To investigate the efficacy and safety of tegaserod, a novel 5‐HT4 receptor partial agonist, in a randomized, double‐blind, placebo‐controlled, 12‐week treatment, multicentre study.
Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonist
TLDR
Colonic sensory and motor function are modulated partly through 5HT3‐receptors, and no currently available treatment provides consistent relief of irritable bowel syndrome.
Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
Visceral hypersensitivity plays a major role in the pathophysiology of irritable bowel syndrome, as shown by balloon distension studies. 5‐HT3 receptors on afferent nerves may modulate visceral
Effect of renzapride on transit in constipation-predominant irritable bowel syndrome.
  • M. Camilleri, S. Mckinzie, +5 authors A. Zinsmeister
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2004
TLDR
Renzapride causes clinically significant dose-related acceleration of CT, particularly ascending colonic emptying; this acceleration of transit is associated with improvement of bowel function in female C-IBS patients.
Review article: cardiac adverse effects of gastrointestinal prokinetics
TLDR
Cisapride (a partial 5‐HT4 receptor agonist) can induce dose‐dependent cardiac adverse effects, including lengthening of the electrocardiographic QT interval, syncopal episodes and ventricular dysrhythmias.
Safety and tolerability of tegaserod in irritable bowel syndrome management.
  • R. Berardi
  • Medicine
    Journal of the American Pharmacists Association : JAPhA
  • 2004
TLDR
Tegaserod is effective in treating multiple IBS symptoms in women with IBS whose primary bowel symptom is constipation, and it is safe and well tolerated.
Efficacy of alosetron in irritable bowel syndrome: a meta‐analysis of randomized controlled trials
TLDR
The present analysis shows that alosetron 1 mg b.i.d. positively impacts global symptoms, and pain and discomfort in non‐constipated IBS female patients.
The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects
TLDR
To determine the prevalence, symptom pattern and impact of the irritable bowel syndrome, across eight European countries, using a standardized methodology, the aim was to establish a standard methodology and establish a baseline for this study.
Review of tegaserod in the treatment of irritable bowel syndrome
TLDR
Patients who were treated with tegaserod had an overall improvement in IBS symptoms as well as in secondary end points, such as abdominal pain and discomfort, stool consistency, change in bowel movements and relief of bloating.
Effect of a slow‐release formula of trimoprostil on intragastric acidity in healthy volunteers
We investigated the effect of a slow‐release formula of trimoprostil, a prostaglandin E2 analogue, at a dose of 3 mg b.d. on circadian intragastric acidity in nine healthy volunteers using ambulatory
...
1
2
3
4
5
...